Topic: Targeted cancer therapy

Download All Articles

A special issue of Cancer Drug Resistance.

Deadline for manuscript submissions: 3 Sep 2018

Share This Special Issue

Guest Editor(s)

  • Dr. Elisa Giovannetti, MD, PhD
    Lab Medical Oncology, VU University Medical Center (VUmc), Cancer Center Amsterdam, The Netherlands.
    Cancer Pharmacology Lab, AIRC Start-Up Unit, University of Pisa, Italy.

    Website | E-mail

  • Dr. Jose Antonio Rodriguez, PhD
    Department of Genetics, Physical Anthropology and Animal Physiology (School of Medicine and Nursing) of the University of the Basque Country (UPV/EHU), Basque Country, Spain.

    Website | E-mail

Special Issue Introduction:

Targeted therapies in cancer aim to specifically block the activity of crucial proteins or signaling pathways necessary for the growth and/or survival of tumor cells. A major breakthrough in targeted cancer therapy was the introduction nearly two decades ago of imatinib, an inhibitor of the BCR-ABL tyrosine kinase for the treatment of chronic myeloid leukemia. Over the last years, significant advances in our understanding of tumor biology have facilitated the development of many drugs targeting not only kinases, but also other protein families and cellular processes. Several of these agents are currently employed or being implemented for the treatment of different hematologic and solid malignancies, such as lung cancer.
The special issue on “Targeted cancer therapy” will include Reviews and Commentaries updating the clinical use of targeted agents in the treatment of different tumor types, and the mechanisms that underlie the action of drugs directed to different types of targets. The special issue will also include Research articles presenting novel outstanding data on all aspects of targeted cancer therapy. All submissions will undergo rigorous peer revision and will be published free of charge upon acceptance.


Biomarkers, personalized medicine, new approaches to cancer treatment, molecularly targeted drugs, mechanisms of targeted drugs, resistance to targeted therapies, novel targets

Submission Information:

Articles of special issue are free of charge for article processing.
For Author Instructions, please refer to
For Online Submission, please login at
Submission Deadline: 3 Sep 2018
Contacts: Elaine Gao, Managing Editor,

Published Articles Download All Articles
  • Resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer

    Nele Van Der Steen , Elisa Giovannetti , Daniela Carbone , Alessandro Leonetti , Christian D. Rolfo , Godefridus J. Peters
    Aberrant activation of the epidermal growth factor receptor (EGFR) is a driving force for cancer growth in a subgroup of non-small cell lung cancer patients. These patients can be identified by the presence of activating EGFR mutations. Currently three generations of EGFR-tyrosine kinase inhibitors (TKI) have been approved by the Food and Drug Administration and European Medicine Agency. This... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:[Online First]. | doi:10.20517/cdr.2018.13
    Published on: 29 Sep 2018  | Viewed:672  | Downloaded:61
    +HTML| PDF
  • Molecular bases of Sorcin-dependent resistance to chemotherapeutic agents

    Ilaria Genovese , Andrea Ilari , Theo Battista , Valerio Chiarini , Francesco Fazi , Annarita Fiorillo , Gianni Colotti
    Soluble resistance-related calcium binding protein (Sorcin) is a protein initially labelled “resistance-related”, since it is co-amplified with ABCB1 in multidrug (MD)-resistant cells. While for years Sorcin overproduction was believed to be a by-product of the co-amplification of its gene with the P-glycoprotein gene, many recent studies view Sorcin as an oncoprotein, playing an important role... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:164-80. | doi:10.20517/cdr.2018.10
    Published on: 19 Sep 2018  | Viewed:1093  | Downloaded:82
    +HTML| PDF
  • Linking tyrosine kinase inhibitor-mediated inflammation with normal epithelial cell homeostasis and tumor therapeutic responses

    Natalia J Gurule , Lynn E. Heasley
    Receptor tyrosine kinases (RTKs) bearing oncogenic mutations in EGFR, ALK and ROS1 occur in a significant subset of lung adenocarcinomas. Tyrosine kinase inhibitors (TKIs) targeting tumor cells dependent on these oncogenic RTKs yield tumor shrinkage, but also a variety of adverse events. Skin toxicities, hematological deficiencies, nausea, vomiting, diarrhea, and headache are among the most... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:118-25. | doi:10.20517/cdr.2018.12
    Published on: 19 Sep 2018  | Viewed:1271  | Downloaded:127
    +HTML| PDF
  • Hitting a moving target: inhibition of the nuclear export receptor XPO1/CRM1 as a therapeutic approach in cancer

    Maria Sendino , Miren Josu Omaetxebarria , Jose Antonio Rodríguez
    Cellular homeostasis crucially relies on the correct nucleocytoplasmic distribution of a vast number of proteins and RNA molecules, which are shuttled in and out of the nucleus by specialized transport receptors. The nuclear export receptor XPO1, also called CRM1, mediates the translocation of hundreds of proteins and several classes of RNA to the cytoplasm, and thus regulates critical... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:139-63. | doi:10.20517/cdr.2018.09
    Published on: 19 Sep 2018  | Viewed:607  | Downloaded:43
    +HTML| PDF
  • Glutamine metabolism in cancer therapy

    Tra-Ly Nguyen , Raúl V. Durán
    The amino acid glutamine plays a key role in the metabolism of highly proliferating cells. During malignant transformation, cancer cells modify the consumption and processing of glutamine to sustain cell growth and proliferation. In some cases, these cancer cells become addicted to glutamine. Thus, targeting the metabolism of glutamine has been developed during last years as a potential... Read more
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:126-38. | doi:10.20517/cdr.2018.08
    Published on: 19 Sep 2018  | Viewed:563  | Downloaded:63
    +HTML| PDF
  • Targeted therapies in cancer: where are we going?

    Elisa Giovannetti , Jose A. Rodriguez
    This article belongs to the Special Issue Targeted cancer therapy
    Cancer Drug Resist 2018;1:82-6. | doi:10.20517/cdr.2018.05
    Published on: 19 Jun 2018  | Viewed:1417  | Downloaded:109
    +HTML| PDF
Cancer Drug Resistance ISSN 2578-532X (Online)
Copyright © 2018 OAE Publishing Inc. All Rights Reserved.